Hims & Hers Health Q1 2026 Earnings Call Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 53 minutes ago
0mins
Should l Buy HIMS?
Source: seekingalpha
- Revenue Growth: Hims & Hers reported a 4% year-over-year revenue increase in Q1 2026, reaching $608 million, although it fell short of expectations, yet the 9% growth in subscribers to nearly 2.6 million indicates a robust expansion of its customer base.
- Strategic Shift: The company made a strategic pivot in its weight loss business, fulfilling over 125,000 shipments of Wegovy products within six weeks of introducing direct access to Novo Nordisk's GLP-1 products, highlighting strong market demand and enhancing brand influence.
- Financial Outlook: The company raised its full-year revenue outlook for 2026 to between $2.8 billion and $3 billion, despite lowering the adjusted EBITDA range to $275 million to $350 million, reflecting profit pressures while expanding into new business areas.
- Restructuring Costs: The strategic shift incurred approximately $33 million in restructuring costs, resulting in a GAAP net loss of $92 million in Q1, illustrating the trade-off between short-term financial challenges and long-term growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 28.270
Low
16.50
Averages
32.95
High
60.00
Current: 28.270
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Health Q1 2026 Earnings Call Insights
- Revenue Growth: Hims & Hers reported a 4% year-over-year revenue increase in Q1 2026, reaching $608 million, although it fell short of expectations, yet the 9% growth in subscribers to nearly 2.6 million indicates a robust expansion of its customer base.
- Strategic Shift: The company made a strategic pivot in its weight loss business, fulfilling over 125,000 shipments of Wegovy products within six weeks of introducing direct access to Novo Nordisk's GLP-1 products, highlighting strong market demand and enhancing brand influence.
- Financial Outlook: The company raised its full-year revenue outlook for 2026 to between $2.8 billion and $3 billion, despite lowering the adjusted EBITDA range to $275 million to $350 million, reflecting profit pressures while expanding into new business areas.
- Restructuring Costs: The strategic shift incurred approximately $33 million in restructuring costs, resulting in a GAAP net loss of $92 million in Q1, illustrating the trade-off between short-term financial challenges and long-term growth potential.
See More
Investors Await CPI Data and Trump's Visit to China
- CPI Data Impact: Investors are awaiting the April Consumer Price Index (CPI) data, with headline inflation projected to rise to 3.7%, which could significantly influence the Federal Reserve's rate decisions and market sentiment.
- Trump's Visit to China: President Trump is set to visit China on Wednesday for discussions with President Xi Jinping, covering trade, artificial intelligence, and Taiwan, which may impact U.S.-China relations and the market performance of related companies.
- Market Dynamics: U.S. stock futures were under pressure early Tuesday, with Nasdaq futures down 0.7% and S&P 500 futures down 0.4%, reflecting investor caution ahead of the CPI report, despite the S&P 500 and Nasdaq closing at record highs on Monday.
- Stock Watch: Tesla's stock fell 2% amid a 9.7% drop in April retail sales, while Quantum Computing Inc shares surged 13% after Q1 revenue skyrocketed to $3.7 million, highlighting the varied market reactions to different companies.
See More
HIMS' AI Healthcare Platform Potential Underestimated by Investors
- Underestimated Potential: Raul Shah of DocShah Financial argues that investors are misjudging HIMS' AI-driven healthcare ambitions, suggesting that partnerships with Novo and Lilly could be the first of many pharma collaborations that reshape the healthcare landscape.
- Significant Shipments: HIMS fulfilled over 125,000 Wegovy shipments within six weeks of launching Novo Nordisk's GLP-1 products, demonstrating its rapid market responsiveness and ability to meet customer demand effectively.
- Enhanced Financial Flexibility: HIMS raised $1 billion in convertible debt last year, providing it with greater financial flexibility to acquire existing healthcare platforms internationally, allowing for swift market expansion in a competitive landscape.
- Optimistic Future Outlook: Despite disappointing Q1 results, HIMS raised its full-year 2026 revenue guidance to $2.8 billion to $3 billion, reflecting the company's confidence in its growth strategy and future market positioning.
See More
U.S. Futures Decline Ahead of Trump's Visit to China
- Futures Market Decline: Dow Jones futures fell by 0.04%, S&P 500 futures decreased by 0.07%, and Nasdaq 100 futures dropped by 0.14%, reflecting investor concerns over Trump's comments on Iran, which may impact market sentiment.
- Presidential Visit to China: Trump is set to visit Beijing on Wednesday, inviting top U.S. executives including Musk, Cook, and Fink to discuss critical issues such as trade and AI, which could have significant implications for U.S.-China relations.
- Federal Reserve Nomination: The Senate is advancing toward confirming Kevin Warsh as the next Fed chair, with markets keenly watching for his potential influence on monetary policy, especially ahead of the upcoming inflation report.
- Rising Oil Prices: Brent crude futures rose by approximately 0.55% and WTI crude futures increased by 0.63%, indicating a positive outlook on energy demand, which may also affect broader economic growth prospects.
See More
Hims & Hers Health Q1 Results Miss Expectations, Shares Drop
- Disappointing Earnings: Hims & Hers Health reported a GAAP EPS of -$0.40 for Q1, a significant drop from $0.20 in the same period last year, leading to an approximately 11% decline in after-hours trading as investors reacted to the disappointing results.
- Weak Revenue Growth: The company generated $608.1M in revenue for Q1, only about 4% higher than Q1 2025, with an 8% year-over-year decline in revenue from its largest market, the US, indicating increased competitive pressure that could impact future market share.
- Subscriber Growth vs. Revenue Decline: While subscribers increased by 9% year-over-year to approximately 2.6 million, the monthly revenue per average subscriber fell by 6% to $80, highlighting challenges in enhancing user value and revenue, which may affect long-term profitability.
- Cautious Future Outlook: The company projects full-year revenue between $2.8B and $3B, with Q2 revenue guidance of $680M to $700M; despite management raising expectations, analysts express concerns over the dual misses in earnings and revenue, emphasizing the company's reliance on the weight-loss market.
See More
Hims & Hers Reports Weak Q1 Results Amid Strategic Shift
- Weak Performance Reasons: Hims & Hers reported Q1 revenue of $608.1 million, a 4% increase year-over-year, but fell short of analyst expectations of $616.85 million, resulting in a 13% drop in after-hours trading.
- Strategic Shift Impact: The company's pivot towards branded GLP-1 drugs incurred approximately $33.5 million in restructuring charges and a $15 million legal settlement, indicating financial strain during the initial phase of the new strategy implementation.
- Future Outlook Improvement: Despite the weak Q1 results, Hims & Hers raised its full-year 2026 revenue guidance to between $2.8 billion and $3.0 billion, with adjusted core profit expected to be between $275 million and $350 million, reflecting confidence in future growth.
- User Growth and Market Reaction: Despite challenges, Hims & Hers saw subscriber growth reach 2.6 million, a 9% year-over-year increase, while retail sentiment on Stocktwits shifted from 'bearish' to 'extremely bullish', indicating market interest in the company's strategic transformation.
See More
Hims & Hers Health Q1 2026 Earnings Call Insights
- Revenue Growth: Hims & Hers reported a 4% year-over-year revenue increase in Q1 2026, reaching $608 million, although it fell short of expectations, yet the 9% growth in subscribers to nearly 2.6 million indicates a robust expansion of its customer base.
- Strategic Shift: The company made a strategic pivot in its weight loss business, fulfilling over 125,000 shipments of Wegovy products within six weeks of introducing direct access to Novo Nordisk's GLP-1 products, highlighting strong market demand and enhancing brand influence.
- Financial Outlook: The company raised its full-year revenue outlook for 2026 to between $2.8 billion and $3 billion, despite lowering the adjusted EBITDA range to $275 million to $350 million, reflecting profit pressures while expanding into new business areas.
- Restructuring Costs: The strategic shift incurred approximately $33 million in restructuring costs, resulting in a GAAP net loss of $92 million in Q1, illustrating the trade-off between short-term financial challenges and long-term growth potential.
See More
Investors Await CPI Data and Trump's Visit to China
- CPI Data Impact: Investors are awaiting the April Consumer Price Index (CPI) data, with headline inflation projected to rise to 3.7%, which could significantly influence the Federal Reserve's rate decisions and market sentiment.
- Trump's Visit to China: President Trump is set to visit China on Wednesday for discussions with President Xi Jinping, covering trade, artificial intelligence, and Taiwan, which may impact U.S.-China relations and the market performance of related companies.
- Market Dynamics: U.S. stock futures were under pressure early Tuesday, with Nasdaq futures down 0.7% and S&P 500 futures down 0.4%, reflecting investor caution ahead of the CPI report, despite the S&P 500 and Nasdaq closing at record highs on Monday.
- Stock Watch: Tesla's stock fell 2% amid a 9.7% drop in April retail sales, while Quantum Computing Inc shares surged 13% after Q1 revenue skyrocketed to $3.7 million, highlighting the varied market reactions to different companies.
See More
HIMS' AI Healthcare Platform Potential Underestimated by Investors
- Underestimated Potential: Raul Shah of DocShah Financial argues that investors are misjudging HIMS' AI-driven healthcare ambitions, suggesting that partnerships with Novo and Lilly could be the first of many pharma collaborations that reshape the healthcare landscape.
- Significant Shipments: HIMS fulfilled over 125,000 Wegovy shipments within six weeks of launching Novo Nordisk's GLP-1 products, demonstrating its rapid market responsiveness and ability to meet customer demand effectively.
- Enhanced Financial Flexibility: HIMS raised $1 billion in convertible debt last year, providing it with greater financial flexibility to acquire existing healthcare platforms internationally, allowing for swift market expansion in a competitive landscape.
- Optimistic Future Outlook: Despite disappointing Q1 results, HIMS raised its full-year 2026 revenue guidance to $2.8 billion to $3 billion, reflecting the company's confidence in its growth strategy and future market positioning.
See More
U.S. Futures Decline Ahead of Trump's Visit to China
- Futures Market Decline: Dow Jones futures fell by 0.04%, S&P 500 futures decreased by 0.07%, and Nasdaq 100 futures dropped by 0.14%, reflecting investor concerns over Trump's comments on Iran, which may impact market sentiment.
- Presidential Visit to China: Trump is set to visit Beijing on Wednesday, inviting top U.S. executives including Musk, Cook, and Fink to discuss critical issues such as trade and AI, which could have significant implications for U.S.-China relations.
- Federal Reserve Nomination: The Senate is advancing toward confirming Kevin Warsh as the next Fed chair, with markets keenly watching for his potential influence on monetary policy, especially ahead of the upcoming inflation report.
- Rising Oil Prices: Brent crude futures rose by approximately 0.55% and WTI crude futures increased by 0.63%, indicating a positive outlook on energy demand, which may also affect broader economic growth prospects.
See More
Hims & Hers Health Q1 Results Miss Expectations, Shares Drop
- Disappointing Earnings: Hims & Hers Health reported a GAAP EPS of -$0.40 for Q1, a significant drop from $0.20 in the same period last year, leading to an approximately 11% decline in after-hours trading as investors reacted to the disappointing results.
- Weak Revenue Growth: The company generated $608.1M in revenue for Q1, only about 4% higher than Q1 2025, with an 8% year-over-year decline in revenue from its largest market, the US, indicating increased competitive pressure that could impact future market share.
- Subscriber Growth vs. Revenue Decline: While subscribers increased by 9% year-over-year to approximately 2.6 million, the monthly revenue per average subscriber fell by 6% to $80, highlighting challenges in enhancing user value and revenue, which may affect long-term profitability.
- Cautious Future Outlook: The company projects full-year revenue between $2.8B and $3B, with Q2 revenue guidance of $680M to $700M; despite management raising expectations, analysts express concerns over the dual misses in earnings and revenue, emphasizing the company's reliance on the weight-loss market.
See More
Hims & Hers Reports Weak Q1 Results Amid Strategic Shift
- Weak Performance Reasons: Hims & Hers reported Q1 revenue of $608.1 million, a 4% increase year-over-year, but fell short of analyst expectations of $616.85 million, resulting in a 13% drop in after-hours trading.
- Strategic Shift Impact: The company's pivot towards branded GLP-1 drugs incurred approximately $33.5 million in restructuring charges and a $15 million legal settlement, indicating financial strain during the initial phase of the new strategy implementation.
- Future Outlook Improvement: Despite the weak Q1 results, Hims & Hers raised its full-year 2026 revenue guidance to between $2.8 billion and $3.0 billion, with adjusted core profit expected to be between $275 million and $350 million, reflecting confidence in future growth.
- User Growth and Market Reaction: Despite challenges, Hims & Hers saw subscriber growth reach 2.6 million, a 9% year-over-year increase, while retail sentiment on Stocktwits shifted from 'bearish' to 'extremely bullish', indicating market interest in the company's strategic transformation.
See More
